Analysis of therapeutic and immunologic effects of r24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma

Cancer

Volumn 88, Issue 12, 2000, Pages 2693-2702

  Kirkwood, John M ^a,e   Mascari, Ruth A ^a   Edington, Howard D ^b   Rabkin, Michael S ^f   Roger S, Day ^c   Whiteside, Theresa L ^a   Vlock, Daniel R ^d   Shipe Spotloe, Janice M ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f Univ of Pittsburgh Cancer Institute ^*

Author keywords

Antibody dependent cellular cytotoxicity gangliosides; Immunoglobulin G3; Monoclonal antibodies

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY R24;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DYSPNEA; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMMUNOPEROXIDASE STAINING; LIVER DYSFUNCTION; LUNG EDEMA; MALE; MELANOMA; METASTASIS; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX PAIN; THROMBOCYTOPENIA; TUMOR BIOPSY; URTICARIA;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANGLIOSIDES; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MICE; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0034659952     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12<2693::AID-CNCR7>3.0.CO;2-3     Document Type: Article

References (21)

1. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985;82:1242-6.
2. Dippold WG, Dienes HP, Knuth A, zum Büschenfelde K-HM. Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial, and normal tissues. Cancer Res 1985;45:3699-705.
3. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, et al. Phase 1 trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988;6:1636-48.
4. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 1987;138:3566-72.
5. Hersey P, Schibeci SD, Townsend P, Burns C, Cheresh DA. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res 1986;46:6083-90.
6. Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JE, et al. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 1987; 139:1763-71.
7. Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin-2 in patients with metastatic melanoma. Cancer Res 1990;50:7490-5.
8. Tveit KM, Fodstad O, Johnnessen JV, Olsnes S. A human melanoma cell line established from xenograft in athymic mice. Br J Cancer 1980;41:724-33.
9. Lindmo T, Davies C, Fodstad O, Morgan A. Stable quantitative differences of antigen expression in human melanoma cells isolated by flow cytometric cell sorting. Int J Cancer 1984;34:507-12.
10. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-63.
11. Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, et al. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 1992;2:355-62.
12. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogan-gliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 1986;83: 7893-7.
13. Dippold W, Bernhard H, zum Buschenfeld K-HM. Immunological response to intrathecal and systemic treatment with ganglioside antibody R-24 in patients with malignant melanoma. Eur J Cancer 1994;30A:137-44.
14. Creekmore S, Urba W, Kopp W, Ewel C, Hecht T, Smith J, et al. Phase IB/II trial of R24 antibody and interleukin-2 (IL-2) in melanoma [abstract]. Proc ASCO 1992;11:345.
15. Claus C, Schlaak J, Dittmayer M, Meyer zum Buschenfelde KH, Dippold W. Inhibition of anti-ganglioside antibody-induced proliferation of human CD8+ T cells by CD16+ natural killer cells. Eur J Immunol 1994;24:1208-12.
16. Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, et al. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 1992;52:851-6.
17. Koppl TA, Halliday WJ, McKenzie IFC. Regulation of cell-mediated immunologic reactivity to Moloney murine sarcoma virus-induced tumors. II. Nature of blocking and unblocking factors in serum. J Natl Cancer Inst 1981;66:1097-102.
18. Kirkwood JM, Wilson J, Whiteside TL, Donnelly S, Herberman RB. Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother 1997;44:137-49.
19. Rabinowich H, Banks M, Reichert T, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996;2:1263-74.
20. Silver HK, Connors JM, Kong S, Karim KA, Spinelli JJ. Survival, response and immune effects in a prospectively randomized study of dose strategy for alpha-N1 interferon. Br J Cancer 1988;58:783-7.
21. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL, et al. Melan-A/MART-1 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 2000; 97:400-5.